Serca Pharmaceuticals presents first-in-class strategy for game-changing, post heart-attack cardioprotection at the European Society of Cardiology Congress 2023

Evidence that 13-M, a unique small molecule disruptor of adrenergic SERCA2 activity reduces infarct size and preserves cardiac function OSLO, Norway, Aug. 29, 2023 /PRNewswire/ — Serca Pharmaceuticals, a cardioprotection company that is developing 13-M, a novel first-in-class treatment…